Skip to main content
Smart Investors Daily
AB

NYSE · ABT

Abbott Laboratories

Healthcare · Medical - Devices

$104.48

Down-$0.51 (-0.49%)

Updated Nov 20, 2026, 1:33 AM

SID Score

6.8/10

Composite research score

Smart Money

48/100

Neutral

Market cap
202.45B
P/E ratio
31.15
Dividend yield
2.26%
52-week range
$81.97 – $124.42
Volume
7.61M
Avg. volume
8.88M

Price performance · ABT

ABT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

ABT closed at $104.48 after 20 trading sessions, up 1.92% for the selected period.

Last close
$104.48
Period change
+1.92%
Period low
$102.51
Period high
$115.51
Daily close
View OHLC price history
ABT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$103.70$105.905$103.26$104.487.61M
Nov 17, 2026$106.50$108.1799$104.585$104.715.92M
Nov 16, 2026$109.55$110.44$107.28$107.458.81M
Nov 13, 2026$108.20$109.28$107.03$108.526.2M
Nov 12, 2026$110.32$110.78$106.89$107.259.96M
Nov 11, 2026$109.88$110.33$108.95$109.298.97M
Nov 10, 2026$109.82$110.84$108.72$110.467.38M
Nov 9, 2026$110.88$111.01$108.93$110.517.84M
Nov 6, 2026$111.08$111.81$109.81$109.938.35M
Nov 5, 2026$117.00$117.07$112.66$113.6010.29M
Nov 4, 2026$112.65$116.215$112.12$115.5112.71M
Nov 3, 2026$109.36$110.615$108.9359$109.407.3M
Nov 2, 2026$106.89$110.48$106.40$110.168.85M
Oct 30, 2026$106.15$106.85$104.60$106.208.44M
Oct 29, 2026$103.79$104.65$102.995$104.577.29M
Oct 28, 2026$101.82$103.93$101.5367$102.645.48M
Oct 27, 2026$102.81$104.28$101.91$103.106.49M
Oct 26, 2026$103.01$105.24$102.90$104.887.84M
Oct 23, 2026$102.28$104.00$101.56$103.7010.3M
Oct 22, 2026$101.50$102.90$99.91$102.5110.66M

Latest ABT news

The latest Smart Investors Daily articles mentioning ABT.

ABT research

Overview

Company profile and research snapshot.

Company profile

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$151.40
Implied upside
—
Analysts
20
ABT recent ratings
DateFirmRatingTarget
Nov 19, 2026Leerink PartnersOutperform—
Oct 27, 2026Argus ResearchHold—
Oct 23, 2026Wells FargoOverweight—
Oct 22, 2026TD CowenBuy—
Oct 22, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 19, 2026

Abbott Laboratories (ABT) Starts VOYAGER CE Trial With New Encantor TAVI System

Abbott Laboratories (NYSE:ABT) has launched its software-guided, balloon-expandable Encantor TAVI system for structural heart procedures. The firm has begun the VOYAGER CE clinical trial, enrolling patients in Europe and Australia to assess the Encantor TAVI platform. Encantor is designed to work alongside Abbott's existing Navitor TAVI system, broadening options for treating severe aortic stenosis. The Encantor TAVI launch and VOYAGER CE trial are important to weigh against the rest of our...

Yahoo · Nov 19, 2026

Arrow Exploration CEO on Icaco success, record production and next drilling targets

Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott talked with Proactive's Stephen Gunnion about the company's latest drilling success at Icaco in Colombia, where the IC-HZ9 well has exceeded production expectations and helped lift corporate output above 7,000 barrels of oil equivalent per day. Abbott highlighted the well's strong performance and reserves potential, explaining how a specialist monobore design with cemented casing and targeted perforations is helping optimise production. Although initial output reached around 3,000 barrels per day, Arrow is managing flow rates to maximise ultimate reservoir recovery rather than short-term production. Looking ahead, the company has identified six additional drilling locations at Icaco, while the recently spudded IC-HZ10 is targeting the Ubaque formation. Abbott outlined the potential for further reserves growth and rapid well payback under Colombia's fiscal regime. The interview also covers Arrow's cash position of more than US$35 million and progress towards securing an extension to the Tapir block contract, a key priority for its longer-term growth plans. For more interviews and updates from companies operating across the energy and natural resources sectors, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications to stay informed about future content. Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy #ArrowExploration #OilAndGas #ColombiaOil #MarshallAbbott #Icaco #OilProduction #OilExploration #EnergyInvesting #Drilling #Ubaque #TapirBlock #EnergyStocks #ProactiveInvestors

Yahoo · Nov 19, 2026

Global Point-of-Care Connectivity Solutions Market to Reach $1.7 Billion by 2032 | Abbott, Roche, Siemens Healthineers and GE HealthCare Accelerate AI-Driven Care

Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Point-of-Care Connectivity Solutions - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global point-of-care connectivity solutions market was valued at US$1.1 billion in 2025 and is projected to reach US$1.7 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.3%. Market growth is being supported by healthcare digitization, increasing adoption of electronic health records, demand for rea

Yahoo · Nov 19, 2026

Point-of-Care/Rapid Diagnostics - Global Strategic Business Report 2026: Capture a $40.7 Billion Market by 2032 with Abbott, Roche, Danaher and Siemens

Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Point-of-Care/Rapid Diagnostics - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global point-of-care/rapid diagnostics market was valued at US$26.1 billion in 2025 and is projected to reach US$40.7 billion by 2032, expanding at a compound annual growth rate (CAGR) of 6.5% during the forecast period. A comprehensive new market report examines the technologies, applications, competitive dynamics and region

AI research layers

Interpretive context generated from the platform’s current data sources.

Abbott Laboratories Stock Performance

Abbott Laboratories shares traded at $104.48, reflecting a modest daily gain of 0.47% per SID market data. Over the trailing one-month period, ABT posted a slight increase of 0.62%, while the three-month and one-year returns showed declines of 8.49% and 16.23%, respectively, underscoring sustained downward pressure over longer timeframes. The stock currently sits above both its 50-day moving average of $103.88 and its 200-day moving average of $101.57, according to Massive/Polygon technical data, suggesting near-term price stabilization following the broader pullback. The 14-day relative strength index stands at 53.6, placing ABT in neutral territory between overbought and oversold conditions. Average daily trading volume registers at approximately 8.88 million shares, while the company carries a market capitalization of $202.45 billion. ABT's beta of 0.751 indicates lower volatility relative to the broader market, consistent with its defensive healthcare sector positioning.

Abbott Laboratories Valuation Analysis

Abbott Laboratories trades at a price-to-earnings ratio of 31.15, per SID market data, reflecting a premium valuation relative to the broader healthcare sector. The company's price-to-book ratio stands at 3.90, according to SEC filings, indicating the market prices ABT shares at nearly four times the company's book value per share. The PEG ratio registers at negative 0.58, a metric that in this context reflects challenges in reconciling the current earnings multiple with forward growth expectations. Abbott currently offers a dividend yield of 2.06%, providing income-oriented investors with a steady return component. The combination of a relatively elevated P/E ratio and a negative PEG ratio suggests that the market continues to assign a premium to Abbott's diversified healthcare portfolio, though the valuation may face scrutiny if earnings growth does not accelerate. The $202.45 billion market capitalization positions Abbott among the largest healthcare companies globally.

Smart Money Activity for ABT

Abbott Laboratories registers a composite smart money score of 48 out of 100, signaling a neutral stance among sophisticated market participants, per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, indicating robust confidence from large asset managers as reflected in 13F institutional filings. In contrast, insider activity scores 9.3 out of 25, with SEC Form 4 filings revealing 16 insider transactions over the past 90 days, comprising 7 purchases and 9 sales. The slight tilt toward insider selling contributes to the subdued insider sentiment reading. Dark pool activity scores 8.5 out of 25, suggesting below-average levels of off-exchange institutional accumulation. Congressional trading activity registers at 5.3 out of 25, reflecting minimal notable legislative trading interest in ABT shares during the observed period. The divergence between strong institutional holdings and weaker insider and dark pool signals creates a mixed overall smart money profile, with large-scale institutional investors maintaining positions while insiders modestly reduce exposure.

Abbott Laboratories Earnings Outlook

Abbott Laboratories has demonstrated consistent earnings execution across recent quarters, per company earnings reports. In the most recent reported quarter, Abbott delivered earnings per share of $1.42, matching the consensus analyst estimate exactly with zero surprise. The prior quarter showed EPS of $1.31, exceeding the $1.28 estimate by $0.03, representing a positive surprise of approximately 2.3%. Before that, Abbott posted EPS of $1.15 against a $1.14 estimate, delivering a $0.01 beat. This sequential earnings progression from $1.15 to $1.31 to $1.42 illustrates a steady upward trajectory in quarterly profitability. Looking ahead, analyst estimates project EPS of $1.42 for the upcoming quarter, identical to the most recently reported figure. The pattern of meeting or modestly exceeding expectations across consecutive quarters reflects Abbott's operational consistency, though the absence of meaningful upside surprises may limit positive earnings-driven catalysts in the near term.

Wall Street Analyst Ratings for ABT

Wall Street coverage of Abbott Laboratories presents a predominantly constructive outlook, though one notable downgrade has emerged, per SID consensus data. On October 27, 2026, Argus Research downgraded ABT from Buy to Hold, representing the most significant recent rating change, according to Wall Street analyst reports. However, the remaining recent coverage reaffirmed positive stances: Wells Fargo maintained its Overweight rating on October 23, while both JP Morgan and Baird reiterated Overweight and Outperform ratings, respectively, on October 22. TD Cowen also maintained its Buy rating on October 22. The concentration of four maintained positive ratings against one downgrade suggests the broader analyst community remains favorable toward Abbott's fundamentals, even as Argus Research's shift to Hold introduces a more cautious perspective. The Argus downgrade is particularly notable given its timing immediately following Abbott's earnings report, where the company matched but did not exceed the $1.42 consensus EPS estimate, potentially reflecting concerns about growth momentum at current valuation levels.